Table 4.
Antibiotic susceptibility of carbapenem‐resistant Pseudomonas aeruginosa clinical isolates with hypersusceptible phenotype
| Isolate | MIC (µg/ml)a | |||||
|---|---|---|---|---|---|---|
| IPM | MER | GEN | FEP | CIP | P/T | |
| PS423 | 8 | 1 | ≤1 | ≤1 | 1 | ≤4 |
| PS424 | ≥16 | ≥16 | ≤1 | 8 | 1 | 8 |
| PS425 | 8 | 0.5 | ≤1 | ≤1 | 1 | ≤4 |
| PS426 | ≥16 | 0.5 | ≤1 | ≤1 | 1 | ≤4 |
| PS428 | ≥16 | 8 | ≤1 | 2 | ≤0.25 | 8 |
| PS429 | ≥16 | 2 | ≤1 | ≤1 | 1 | ≤4 |
| PS431 | ≥16 | 4 | ≤1 | 2 | 0.5 | 8 |
| PS432 | 8 | 0.25 | ≤1 | ≤1 | 0.5 | ≤4 |
Susceptibilities determined by the Vitek2.
a
Abbreviations: P/T, piperacillin/tazobactam; FEP, cefepime; IPM, imipenem; MEM, meropenem; GEN, gentamicin; CIP, ciprofloxacin